Type 2 diabetes
Conditions
Interventions
Experimental group:This is an acute, randomized, placebo-controlled, crossover clinical trial of Duzhibao (liquid version) in T2DM. Subjects were randomly assigned to either the pure water control gro
Control group:This is an acute, randomized, placebo-controlled, crossover clinical trial of Duzhibao (liquid version) in T2DM. Subjects were randomly assigned to either the pure water control group or
Sponsors
Shanghai Fengxian Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.The subjects are between 18 and 80 years old; 2.The subjects meet the WHO criteria for T2DM diagnosis: FPG>=7.0 mmol/L, 2 h glucose >=11.1 mmol/L, or glycated hemoglobin (HbA1c) >= 48 mmol/mol (6.5%); 3.Body mass index (BMI) >= 18.5 kg/m^2, HbA1c>=53 mmol/mol [7.0%], FPG <= 13 mmol/L. 4.The subject voluntarily participates in this clinical study and completes the written informed consent form.
Exclusion criteria
Exclusion criteria: (1) Acute and chronic gastrointestinal disorders such as peptic ulcers or hernias, hyperthyroidism, hypothyroidism, uncontrolled hypertension, hepatic or renal insufficiency (alanine aminotransferase [ALT], thyroid gland deficiency)Aspartate aminotransferase [AST] or serum creatinine (Scr) 1.5 times higher than normal, gestational or fragile diabetes mellitus, any acute infection, drug or alcohol abuse, myocardial infarction, cardiac surgery, or stroke within the previous 3 months; (2) Persons who cannot follow the study procedure, including persons with mental illnesses; (3) People who are allergic or intolerant to the products used in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postprandial blood glucose; | — |
Countries
China
Contacts
Public ContactChen Peihong
Endocrinology and Metabolism Department, Central Hospital of Fengxian District, Shanghai
Outcome results
None listed